ProShares UltraShort Silver

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Defiance Daily Short Digitizing the Economy ETF

ProShares Bitcoin Strategy ETF

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily Gold Miners Bear 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

VS TR -1x Short VIX Futures ETF

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Guggenheim Solar ETF

ProShares Ultra Silver

MicroSectors Gold Miners 3X Leveraged ETN

ProShares Trust ProShares Short Bitcoin Strategy ETF

SPDR S&P Regional Banking ETF

Direxion Daily Gold Miners Bull 3X ETF

ProShares Ultra Bloomberg Natural Gas

iShares Silver Trust

VS TR 2x Long VIX Futures ETF

United States Oil Fund

Urban Outfitters Inc. Common Stock

Snowflake Inc. Class A Common Stock

MINISO Group Holding Limited American Depositary Shares each representing four Ordinary Shares

AgEagle Aerial Systems Inc. Common Stock

CleanSpark Inc. Common Stock

Aquestive Therapeutics Inc. Common Stock

ChargePoint Holdings Inc. Common Stock

Marathon Digital Holdings Inc. Common Stock

Dana Incorporated Common Stock

Riot Platforms Inc. Common Stock

Fastenal Company Common Stock

Edible Garden AG Incorporated Common Stock

SolarEdge Technologies Inc. Common Stock

Enphase Energy Inc. Common Stock

Hims & Hers Health Inc. Class A Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Virgin Galactic Holdings Inc. Common Stock

IBO (Listing Market - NYSE Amex Network B F)

UnitedHealth Group Incorporated Common Stock (DE)

CVS Health Corporation Common Stock

Click here to get full coverage on Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Yahoo Finance

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout”  Yahoo Finance

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Yahoo Finance

Click here to get full coverage on Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025  Business Wire

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire

Click here to get full coverage on Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy - Stock Titan

Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy  Stock Titan

Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy - Stock Titan

Click here to get full coverage on HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq

HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More  Nasdaq

HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

Harrow: A Name I Am Accumulating (NASDAQ:HROW)  Seeking Alpha

Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Harrow to Present at Two Investor Conferences in May - Business Wire

Harrow to Present at Two Investor Conferences in May  Business Wire

Harrow to Present at Two Investor Conferences in May - Business Wire

Click here to get full coverage on Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives  Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Click here to get full coverage on Harrow Announces First-Quarter 2025 Financial Results - Stock Titan

Harrow Announces First-Quarter 2025 Financial Results  Stock Titan

Harrow Announces First-Quarter 2025 Financial Results - Stock Titan

Click here to get full coverage on Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)  Seeking Alpha

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Click here to get full coverage on Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Nasdaq

Harrow (HROW) Q4 Earnings and Revenues Top Estimates  Nasdaq

Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Nasdaq

Click here to get full coverage on What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings  Yahoo Finance

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings - Yahoo Finance

Click here to get full coverage on Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership  Stock Titan

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Click here to get full coverage on Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Business Wire

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results  Business Wire

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Business Wire

Click here to get full coverage on Noteworthy Friday Option Activity: SNOW, OUST, HROW - Nasdaq

Noteworthy Friday Option Activity: SNOW, OUST, HROW  Nasdaq

Noteworthy Friday Option Activity: SNOW, OUST, HROW - Nasdaq

Click here to get full coverage on Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...  Yahoo Finance

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance

Click here to get full coverage on TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News  Stock Titan

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

Click here to get full coverage on Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee - Stock Titan

Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee  Stock Titan

Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee - Stock Titan

Click here to get full coverage on Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27 - Stock Titan

Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27  Stock Titan

Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27 - Stock Titan

Click here to get full coverage on Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... - Yahoo Finance

Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...  Yahoo Finance

Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... - Yahoo Finance

Click here to get full coverage on HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto - GuruFocus

HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto  GuruFocus

HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto - GuruFocus

Click here to get full coverage on HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus

HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne  GuruFocus

HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus

Click here to get full coverage on Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus

Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO  GuruFocus

Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus

Click here to get full coverage on Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...  Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans | HROW Stock News - GuruFocus

Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans | HROW Stock News  GuruFocus

Harrow (HROW) Sees Promising Revenue Growth and Expansion Plans | HROW Stock News - GuruFocus

Click here to get full coverage on Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients  Business Wire

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire

Click here to get full coverage on Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW)  Seeking Alpha

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Click here to get full coverage on Major Breakthrough: Harrow Ends TRIESENCE Shortage Crisis with 5-Year Manufacturing Deal - Stock Titan

Major Breakthrough: Harrow Ends TRIESENCE Shortage Crisis with 5-Year Manufacturing Deal  Stock Titan

Major Breakthrough: Harrow Ends TRIESENCE Shortage Crisis with 5-Year Manufacturing Deal - Stock Titan

Click here to get full coverage on HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW St - GuruFocus

HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW St  GuruFocus

HROW Forecasts Surpassing $280 Million Revenue by 2025 | HROW St - GuruFocus

Click here to get full coverage on Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025  Seeking Alpha

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha

Click here to get full coverage on Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance

Harrow, Inc. (HROW): A Bull Case Theory  Yahoo Finance

Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth - GuruFocus

Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth  GuruFocus

Harrow Health (HROW) Reports Q1 Revenue Miss Despite Growth - GuruFocus

Click here to get full coverage on Harrow Inc (HROW) Q1 2025 Earnings: EPS of -$0.50 Misses Estimate, Revenue at $47.8M Below Forecast - GuruFocus

Harrow Inc (HROW) Q1 2025 Earnings: EPS of -$0.50 Misses Estimate, Revenue at $47.8M Below Forecast  GuruFocus

Harrow Inc (HROW) Q1 2025 Earnings: EPS of -$0.50 Misses Estimate, Revenue at $47.8M Below Forecast - GuruFocus

Click here to get full coverage on NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - PR Newswire

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)  PR Newswire

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - PR Newswire

Click here to get full coverage on Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients - Business Wire

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients  Business Wire

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients - Business Wire

Click here to get full coverage on Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi  GuruFocus

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus

Click here to get full coverage on Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Harrow Soars On Preliminary Q4 Results, Revenue Outlook  RTTNews

Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Click here to get full coverage on Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol  Seeking Alpha

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha

Click here to get full coverage on Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share - marketscreener.com

Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share  marketscreener.com

Earnings Flash (HROW) HARROW INC. Reports Q1 Loss $0.38 Per Share - marketscreener.com

Click here to get full coverage on Noteworthy Tuesday Option Activity: BECN, HROW, HUM - Nasdaq

Noteworthy Tuesday Option Activity: BECN, HROW, HUM  Nasdaq

Noteworthy Tuesday Option Activity: BECN, HROW, HUM - Nasdaq

Click here to get full coverage on Harrow Inc (HROW) Shares Gap Down to $24.695 on Apr 28 - GuruFocus

Harrow Inc (HROW) Shares Gap Down to $24.695 on Apr 28  GuruFocus

Harrow Inc (HROW) Shares Gap Down to $24.695 on Apr 28 - GuruFocus

Click here to get full coverage on Examining the Future: Harrow's Earnings Outlook - Nasdaq

Examining the Future: Harrow's Earnings Outlook  Nasdaq

Examining the Future: Harrow's Earnings Outlook - Nasdaq

Click here to get full coverage on Harrow: Q1 Earnings Snapshot - San Francisco Chronicle

Harrow: Q1 Earnings Snapshot  San Francisco Chronicle

Harrow: Q1 Earnings Snapshot - San Francisco Chronicle

Click here to get full coverage on Harrow’s Focus - Reviving Old Drugs In A Crowded Market (HROW) - Seeking Alpha

Harrow’s Focus - Reviving Old Drugs In A Crowded Market (HROW)  Seeking Alpha

Harrow’s Focus - Reviving Old Drugs In A Crowded Market (HROW) - Seeking Alpha

Click here to get full coverage on Harrow Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Harrow Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Harrow Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail

Harrow Health (HROW) Gets a Buy from Craig-Hallum  The Globe and Mail

Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail

Click here to get full coverage on Harrow to Report First Quarter 2025 Financial Results After Mark - GuruFocus

Harrow to Report First Quarter 2025 Financial Results After Mark  GuruFocus

Harrow to Report First Quarter 2025 Financial Results After Mark - GuruFocus

Click here to get full coverage on Harrow: Q1 Earnings Snapshot - CT Insider

Harrow: Q1 Earnings Snapshot  CT Insider

Harrow: Q1 Earnings Snapshot - CT Insider

Click here to get full coverage on Where Harrow Stands With Analysts - Benzinga

Where Harrow Stands With Analysts  Benzinga

Where Harrow Stands With Analysts - Benzinga

Click here to get full coverage on Harrow Announces Second Quarter 2024 Financial Results - Business Wire

Harrow Announces Second Quarter 2024 Financial Results  Business Wire

Harrow Announces Second Quarter 2024 Financial Results - Business Wire

Click here to get full coverage on Harrow Announces Nashville Expansion - Business Wire

Harrow Announces Nashville Expansion  Business Wire

Harrow Announces Nashville Expansion - Business Wire

Click here to get full coverage on Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch - GuruFocus

Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch  GuruFocus

Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch - GuruFocus

Click here to get full coverage on Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. - Business Wire

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.  Business Wire

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. - Business Wire

Click here to get full coverage on Harrow (HROW) Broadens Vevye Program to Include Klarity-C Patien - GuruFocus

Harrow (HROW) Broadens Vevye Program to Include Klarity-C Patien  GuruFocus

Harrow (HROW) Broadens Vevye Program to Include Klarity-C Patien - GuruFocus

Click here to get full coverage on Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL  Business Wire

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Harrow Health Inc (HROW)

Price Chart

Key Statistics

Technicals

About HROW

Latest News

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Yahoo Finance

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire

Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy - Stock Titan

Advanced Charts

Top Gainers

Top Losers